Nothing Special   »   [go: up one dir, main page]

About: Medarex

An Entity of Type: agent, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Medarex (former NASDAQ symbol: MEDX ) was an American biopharmaceutical company based in Princeton, New Jersey, with manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California. In 2009, Medarex was purchased by Bristol Myers Squibb. Medarex developed some of the first transgenic mice with humanized immune systems, in order to generate fully human antibodies. Many of the on-market monoclonal antibodies have been derived from this platform.

Property Value
dbo:abstract
  • Medarex (former NASDAQ symbol: MEDX ) was an American biopharmaceutical company based in Princeton, New Jersey, with manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California. In 2009, Medarex was purchased by Bristol Myers Squibb. Medarex developed monoclonal antibodies to CTLA-4 and PD-1, which are proteins on the surface of T cells. T cells attack cancer cells, but CTLA-4 and PD-1 act as "brakes" on the T cell's anti-cancer activities. The monoclonal antibodies bind to these proteins and block them, releasing the T cell to attack cancer cells. Several monoclonal antibodies developed by Medarex have been approved for disease therapy. In 2009, the U.S. Food and Drug Administration approved Simponi, a human monoclonal antibody to tumor necrosis factor alpha co-developed with Johnson & Johnson's Janssen Biotech, for treatment of arthritis. In 2011, the U.S. FDA approved ipilimumab, a monoclonal antibody to CTLA-4, for treatment of metastatic melanoma.In 2014, the U.S. FDA approved nivolumab, a monoclonal antibody to PD-1, for treatment of advanced melanoma. Its use was expanded to the treatment of squamous non-small-cell lung carcinoma in 2015. Medarex developed some of the first transgenic mice with humanized immune systems, in order to generate fully human antibodies. Many of the on-market monoclonal antibodies have been derived from this platform. (en)
dbo:fate
  • Acquired byBristol Myers Squibb (en)
dbo:foundingYear
  • 1987-01-01 (xsd:gYear)
dbo:headquarter
dbo:industry
dbo:parentCompany
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 10806484 (xsd:integer)
dbo:wikiPageLength
  • 6325 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1095742197 (xsd:integer)
dbo:wikiPageWikiLink
dbp:fate
  • Acquired by Bristol Myers Squibb (en)
dbp:founder
  • Dr. Edward D. Ball (en)
  • Dr. Michael W. Fanger (en)
  • Dr. Paul M. Guyre (en)
dbp:hqLocation
dbp:industry
dbp:name
  • Medarex (en)
dbp:parent
  • Bristol Myers Squibb (en)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Medarex (former NASDAQ symbol: MEDX ) was an American biopharmaceutical company based in Princeton, New Jersey, with manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California. In 2009, Medarex was purchased by Bristol Myers Squibb. Medarex developed some of the first transgenic mice with humanized immune systems, in order to generate fully human antibodies. Many of the on-market monoclonal antibodies have been derived from this platform. (en)
rdfs:label
  • Medarex (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
foaf:name
  • Medarex (en)
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License